$EXEL - On our trading list. Piper Sandler commented on drug data out today. Looks good according to Piper. Overweight rating and $35 price target.Exelixis data 'impressive,' support accelerated approval, says Piper SandlerExelixis last night reported interim Phase Ib COSMIC-021 expansion data of Cabometyx with atezolizumab in 44 men with metastatic castration-resistant prostate cancer showing an "impressive" 32% objective response rate and 80% disease control rate with 8.3 month median duration of response, Piper Sandler analyst Edward Tenthoff tells investors in a research note. The analyst believes these data support Exelixis' plan to file for accelerated approval metastatic castration-resistant prostate cancer in early 2021. He reiterates an Overweight rating on the shares with a $35 price target. $EXEL, Exelixis, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page